Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ZOCGBP

(ZOCGBP)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
06/02/20241:00PMPR Newswire (Canada)/R E P E A T -- Media Advisory - Minister Wilkinson announces funding and measures to protect Southern Resident killer whales/
06/02/20241:00PMPR Newswire (Canada)/R E P R I S E -- Avis aux médias - Le ministre Wilkinson annonce des investissements et des mesures pour protéger les épaulards résidents du Sud/
06/02/202412:40PMPR Newswire (US)GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
06/02/202412:40PMPR Newswire (Canada)GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
06/02/202412:30PMGlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
06/02/202412:30PMGlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingTG:2GHMerus NV
06/02/202412:30PMGlobeNewswire Inc.Merus : présentation des données provisoires sur le MCLA-145 en monothérapie et en association avec le pembrolizumab lors du congrès annuel 2024 de l’ASCO®TG:2GHMerus NV
06/02/202412:30PMBusiness WireCatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
06/02/202412:30PMGlobeNewswire Inc.Merus präsentiert Zwischenergebnisse zu MCLA-145 als Monotherapie und in Kombination mit Pembrolizumab auf der ASCO®-Jahrestagung 2024TG:2GHMerus NV
06/02/202412:30PMPR Newswire (US)Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
06/02/202412:25PMPR Newswire (Canada)Avis aux médias - Agents de la paix en services correctionnels - Le TSO : pas juste dans la santé qu'il y en a
06/02/202412:09PMBusiness WireStronger Than Ever: Adani Portfolio Delivers Record Performance
06/02/202411:32AMPR Newswire (US)Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
06/02/202411:31AMGlobeNewswire Inc.KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
06/02/202411:31AMGlobeNewswire Inc.KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
06/02/202411:27AMGlobeNewswire Inc.Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
06/02/202411:24AMPR Newswire (US)Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
06/02/202411:13AMPR Newswire (US)LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
06/02/202411:00AMPR Newswire (US)WafaTech Unveils Comprehensive Suite of Cloud, Connectivity, and ICT Solutions for Saudi Arabia
06/02/202411:00AMPR Newswire (US)Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
06/02/202410:56AMBusiness WireBelantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myelomaNYSE:GSKGSK plc
06/02/202410:55AMGlobeNewswire Inc.Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection StudyNASDAQ:SEERSeer Inc
06/02/202410:45AMPR Newswire (US)ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
06/02/202410:30AMPR Newswire (Canada)En pleine négociation, les intervenantes en petite enfance de la FIPEQ-CSQ sont solidaires de l'organisme Ma place au travail
06/02/202410:25AMPR Newswire (US)ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
06/02/202410:01AMBusiness WirePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)NASDAQ:PBYIPuma Biotechnology Inc
06/02/202410:00AMGlobeNewswire Inc.Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple Blood Test
06/02/202410:00AMGlobeNewswire Inc.ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerNASDAQ:ALXOALX Oncology Holdings Inc
06/02/202410:00AMPR Newswire (Canada)Adoption à l'unanimité du projet de loi no 56 - Un troisième jalon de la réforme du droit de la famille : pour protéger les enfants naissant hors mariage
06/02/202410:00AMPR Newswire (US)MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer